List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8013676/publications.pdf Version: 2024-02-01

		22153	32842
327	13,142	59	100
papers	citations	h-index	g-index
332	332	332	17025
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. Journal of Neurosurgical Sciences, 2023, 67, .	0.6	5
2	Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples. Journal of Clinical Pathology, 2023, 76, 671-677.	2.0	1
3	Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Cancer Immunology, Immunotherapy, 2022, 71, 45-55.	4.2	39
4	Does Locally Advanced Thyroid Cancer Have Different Features? Results from a Single Academic Center. Journal of Personalized Medicine, 2022, 12, 221.	2.5	3
5	The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma Urologic Oncology: Seminars and Original Investigations, 2022, 40, 108.e19-108.e25.	1.6	8
6	Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis. Journal of Personalized Medicine, 2022, 12, 685.	2.5	5
7	Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation―Techniques. Frontiers in Endocrinology, 2022, 13, .	3.5	7
8	A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights. International Journal of Molecular Sciences, 2022, 23, 7872.	4.1	0
9	Methylation study of the Paris system for reporting urinary (TPS) categories. Journal of Clinical Pathology, 2021, 74, 102-105.	2.0	7
10	The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 131.e17-131.e21.	1.6	10
11	Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response. Cancers, 2021, 13, 257.	3.7	10
12	Dilation of Brain Veins and Perivascular Infiltration by Glioblastoma Cells in an In Vivo Assay of Early Tumor Angiogenesis. BioMed Research International, 2021, 2021, 1-11.	1.9	1
13	How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquidâ€based cytology: Role of TERT promoter and BRAF V600E mutation analysis. Cancer Cytopathology, 2021, 129, 819-829.	2.4	12
14	The Role of Cytology in the Diagnosis of Subcentimeter Thyroid Lesions. Diagnostics, 2021, 11, 1043.	2.6	6
15	Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. Human Pathology, 2021, 118, 42-48.	2.0	11
16	Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. Diagnostics, 2021, 11, 10.	2.6	13
17	Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2021, 106, 3162-3169.	3.5	4
18	The Diagnosis of Hyalinizing Trabecular Tumor: A Difficult and Controversial Thyroid Entity. Head and Neck Pathology, 2020, 14, 778-784.	2.6	17

#	Article	IF	CITATIONS
19	The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Leukemia and Lymphoma, 2020, 61, 1133-1139.	1.3	6
20	PD‣1 and thyroid cytology: A possible diagnostic and prognostic marker. Cancer Cytopathology, 2020, 128, 177-189.	2.4	13
21	ALK-negative anaplastic large cell lymphoma with "Hodgkin-like―cytomorphology and nuclear expression of PAX5. Pathology Research and Practice, 2020, 216, 152724.	2.3	2
22	Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood–Brain Barrier. Cancers, 2020, 12, 18.	3.7	19
23	Relevance of rosette patterns in variants of papillary thyroid carcinoma. Cytopathology, 2020, 31, 533-540.	0.7	2
24	c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. Cancers, 2020, 12, 638.	3.7	52
25	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 269-277.	2.8	13
26	lgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. Blood, 2020, 136, 30-31.	1.4	0
27	Germ Cell Neoplasia in situ (GCNIS) in Testis-Sparing Surgery (TSS) for Small Testicular Masses (STMs). Frontiers in Endocrinology, 2019, 10, 512.	3.5	4
28	A large series of hyalinizing trabecular tumors: Cytomorphology and ancillary techniques on fine needle aspiration. Cancer Cytopathology, 2019, 127, 390-398.	2.4	11
29	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Update and Diagnostic Considerations—a Review. Endocrine Pathology, 2019, 30, 155-162.	9.0	25
30	Glioblastoma endothelium drives bevacizumabâ€induced infiltrative growth <i>via</i> modulation of PLXDC1. International Journal of Cancer, 2019, 144, 1331-1344.	5.1	22
31	Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents. Clinical Epigenetics, 2019, 11, 2.	4.1	15
32	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. Pathology and Oncology Research, 2019, 25, 513-520.	1.9	5
33	34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 306-310.	1.2	3
34	RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases. Annals of Surgery, 2019, 269, 120-126.	4.2	167
35	To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniques—The Useful Role of Liquid-Based Cytology. Archives of Pathology and Laboratory Medicine, 2018, 142, 299-307.	2.5	22
36	Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia. Hematological Oncology, 2018, 36, 600-603.	1.7	10

#	Article	IF	CITATIONS
37	Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules. Cytopathology, 2018, 29, 418-427.	0.7	17
38	The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration. Cancer Cytopathology, 2018, 126, 200-206.	2.4	12
39	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood, 2018, 131, 2413-2425.	1.4	223
40	Vitamin D deficiency and supplementation in patients with aggressive Bâ€cell lymphomas treated with immunochemotherapy. Cancer Medicine, 2018, 7, 270-281.	2.8	44
41	Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. Modern Pathology, 2018, 31, 1361-1366.	5.5	29
42	Noninvasive follicular thyroid neoplasm with papillaryâ€ <b>ŀ</b> ike nuclear features in the pediatric age group. Cancer Cytopathology, 2018, 126, 27-35.	2.4	28
43	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features <scp>(NIFTP):</scp> Implications for the risk of malignancy <scp>(ROM)</scp> in the Bethesda System for Reporting Thyroid Cytopathology <scp>(TBSRTC)</scp> . Cancer Cytopathology, 2018, 126, 20-26.	2.4	62
44	The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 324-329.	1.2	4
45	Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. Acta Neurochirurgica, 2018, 160, 2387-2391.	1.7	2
46	Levetiracetam enhances the temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Cancer Cell International, 2018, 18, 136.	4.1	34
47	Ancillary molecular testing of indeterminate thyroid nodules. Cancer Cytopathology, 2018, 126, 654-671.	2.4	22
48	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. Apmis, 2018, 126, 705-709.	2.0	15
49	VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. BMC Cancer, 2018, 18, 553.	2.6	11
50	Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death and Disease, 2018, 9, 841.	6.3	182
51	Morphological features that can predict <i>BRAF</i> <sup><i>V600E</i></sup> â€mutated carcinoma in paediatric thyroid cytology. Cytopathology, 2017, 28, 55-64.	0.7	11
52	SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. Prostate, 2017, 77, 597-603.	2.3	4
53	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. British Journal of Cancer, 2017, 116, 1279-1286.	6.4	37
54	When Somatic Mutations Are Associated With a Higher Aggressive Behavior—A Story of Announced Evidence. JAMA Oncology, 2017, 3, 1427.	7.1	0

#	Article	IF	CITATIONS
55	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro-Oncology, 2017, 19, 1097-1108.	1.2	56
56	The role of miRNAs in the evaluation of follicular thyroid neoplasms: an overview of literature. Journal of the American Society of Cytopathology, 2017, 6, 96-104.	0.5	3
57	Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy. Hematological Oncology, 2017, 35, 64-65.	1.7	5
58	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). Pathology Research and Practice, 2017, 213, 1078-1081.	2.3	10
59	Cytopathology of Follicular Cell Nodules. Advances in Anatomic Pathology, 2017, 24, 45-55.	4.3	11
60	The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature. Cancer Cytopathology, 2017, 125, 594-603.	2.4	16
61	The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation. Endocrine, 2017, 56, 379-387.	2.3	Ο
62	Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. Oncotarget, 2017, 8, 3746-3760.	1.8	8
63	Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget, 2017, 8, 13223-13239.	1.8	30
64	Divergent gastrointestinal stromal tumors in syndromic settings. Cancer Genetics, 2016, 209, 354-358.	0.4	10
65	Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive. Journal of Clinical Oncology, 2016, 34, e107-e109.	1.6	5
66	The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms. Endocrine, 2016, 54, 723-732.	2.3	36
67	Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features on liquidâ€based cytology: Some insights into their identification. Cancer Cytopathology, 2016, 124, 699-710.	2.4	78
68	CD 68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. Cancer Medicine, 2016, 5, 398-406.	2.8	28
69	The potential of liquidâ€based cytology in lymph node cytological evaluation: the role of morphology and the aid of ancillary techniques. Cytopathology, 2016, 27, 50-58.	0.7	10
70	Impaired functional responses in follicular lymphoma CD8 <sup>+</sup> TIM-3 <sup>+</sup> T lymphocytes following TCR engagement. Oncolmmunology, 2016, 5, e1224044.	4.6	32
71	Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. Thrombosis Research, 2016, 141, 106-111.	1.7	34
72	Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. Stroke, 2016, 47, 886-890.	2.0	52

#	Article	IF	CITATIONS
73	Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical and Translational Oncology, 2016, 18, 988-995.	2.4	16
74	Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 628-634.	1.3	24
75	c-Myc expression as a key-marker in the colorectal cancer resistance to EGFR inhibitors Journal of Clinical Oncology, 2016, 34, e15034-e15034.	1.6	3
76	The role of fine-needle aspiration in the thyroid nodules of elderly patients. Oncotarget, 2016, 7, 11850-11859.	1.8	9
77	SOCS3 immunohistochemical expression to support the 2005 International Society of Urological Pathology (ISUP) modified Gleason grading system Journal of Clinical Oncology, 2016, 34, 216-216.	1.6	0
78	Translational impact of patient-derived glioblastoma tumorspheres Journal of Clinical Oncology, 2016, 34, 2025-2025.	1.6	0
79	Circulating hematopoietic stem cells and putative intestinal stem cells in coeliac disease. Journal of Translational Medicine, 2015, 13, 220.	4.4	10
80	Uncommon <i>BRAF</i> mutations in the follicular variant of thyroid papillary carcinoma: New insights. Cancer Cytopathology, 2015, 123, 593-602.	2.4	22
81	ls thyroid gland only a "land―for primary malignancies? role of morphology and immunocytochemistry. Diagnostic Cytopathology, 2015, 43, 374-380.	1.0	19
82	A BMP7 Variant Inhibits Tumor Angiogenesis In Vitro and In Vivo through Direct Modulation of Endothelial Cell Biology. PLoS ONE, 2015, 10, e0125697.	2.5	14
83	Well-differentiated Thyroid Cancer With a Minor Poorly Differentiated Component. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 196-201.	1.2	3
84	PDGFRA-mutant syndrome. Modern Pathology, 2015, 28, 954-964.	5.5	50
85	Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome. Platelets, 2015, 26, 751-757.	2.3	28
86	P-164 Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma HENT1 positive: back to the future. Annals of Oncology, 2015, 26, iv47.	1.2	1
87	A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. European Journal of Human Genetics, 2015, 23, 1673-1678.	2.8	15
88	Endothelial Progenitor Cell Dysfunction in Myelodysplastic Syndromes: Possible Contribution of a Defective Vascular Niche to Myelodysplasia. Neoplasia, 2015, 17, 401-409.	5.3	24
89	Endoscopic ultrasound-guided fine needle tissue acquisition biopsy samples do not allow a reliable proliferation assessment of gastrointestinal stromal tumours. Digestive and Liver Disease, 2015, 47, 291-295.	0.9	18
90	VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. Neurology, 2015, 84, 1906-1908.	1.1	22

#	Article	IF	CITATIONS
91	Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer Journal, 2015, 5, e323.	6.2	32
92	Pituitary-tumour-transforming-gene 1 expression in testicular cancer. Andrologia, 2015, 47, 427-432.	2.1	17
93	An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. Blood Cancer Journal, 2015, 5, e370-e370.	6.2	0
94	Systemic mastocytosis mimicking carcinoid syndrome. Endocrine, 2015, 48, 718-719.	2.3	2
95	The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology. PLoS ONE, 2015, 10, e0132939.	2.5	21
96	miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget, 2015, 6, 37241-37256.	1.8	42
97	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death and Disease, 2014, 5, e1223-e1223.	6.3	57
98	Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker. Journal of Molecular Diagnostics, 2014, 16, 467-476.	2.8	16
99	Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience. Cancer Cytopathology, 2014, 122, 527-535.	2.4	47
100	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leukemia and Lymphoma, 2014, 55, 270-275.	1.3	43
101	Thyroglossal duct cyst cancer most likely arises from a thyroid gland remnant. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 67-72.	2.8	22
102	Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 247-248.	2.8	13
103	Papillary thyroid microcarcinoma: a painstaking category to manage. Clinical Endocrinology, 2014, 81, 785-786.	2.4	3
104	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood, 2014, 123, 3677-3679.	1.4	22
105	Morphological parameters able to predict <scp><i>BRAF<sup>V600E</sup></i></scp> â€mutated malignancies on thyroid fineâ€needle aspiration cytology: Our institutional experience. Cancer Cytopathology, 2014, 122, 883-891.	2.4	39
106	Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. Blood Transfusion, 2014, 12 Suppl 1, s367-74.	0.4	17
107	Primary Trombocythemia in Children and Adolescents Includes Different Subtypes Compared to Adult Essential Thrombocythemia. Blood, 2014, 124, 1865-1865.	1.4	0
108	Abnormal Mirna Expression Profile and Cytokine Production in Myelodysplastic Vascular Niche. Blood, 2014, 124, 1890-1890.	1.4	0

#	Article	IF	CITATIONS
109	Alterations of negative regulators of cytokine signalling in immunodeficiencyâ€related nonâ€Hodgkin lymphoma. Hematological Oncology, 2013, 31, 22-28.	1.7	14
110	Image-Enhanced Endoscopy with I-scan Technology for the Evaluation of Duodenal Villous Patterns. Digestive Diseases and Sciences, 2013, 58, 1287-1292.	2.3	26
111	Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death and Differentiation, 2013, 20, 396-407.	11.2	53
112	<i>BRAF</i> (V600E) mutation analysis on liquidâ€based cytologyâ€processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathology, 2013, 121, 291-297.	2.4	104
113	Can a geneâ€expression classifier with high negative predictive value solve the indeterminate thyroid fineâ€needle aspiration dilemma?. Cancer Cytopathology, 2013, 121, 403-403.	2.4	6
114	Blood and endothelial cells: together through thick and thin. Blood, 2013, 121, 248-249.	1.4	3
115	Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochirurgica, 2013, 155, 33-40.	1.7	27
116	Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma. Neoplasia, 2013, 15, 773-IN27.	5.3	19
117	Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. Thrombosis Research, 2013, 131, 238-243.	1.7	17
118	Detection of ectopic thyroid remnants: A serious diagnostic dilemma. When molecular biology and immunohistochemistry can solve the problem. Pathology Research and Practice, 2013, 209, 59-61.	2.3	13
119	Epigenetic silencing of <i>Id4</i> identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer, 2013, 119, 1004-1012.	4.1	42
120	Endothelial Progenitor Cells in HIV-Positive Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, e22-e23.	2.1	2
121	<i>MGA</i> , a suppressor of <i>MYC</i> , is recurrently inactivated in high risk chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1087-1090.	1.3	81
122	Mantle cell lymphoma relapsing at the lymphedematous arm Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013016.	1.3	2
123	Fine-needle tissue acquisition from subepithelial lesions using a forward-viewing linear echoendoscope. Endoscopy, 2013, 46, 39-45.	1.8	67
124	Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. European Journal of Endocrinology, 2013, 168, 853-859.	3.7	62
125	Small lymphocytic lymphoma in a patient with Fabry disease. Leukemia and Lymphoma, 2013, 54, 184-185.	1.3	6
126	KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. British Journal of Cancer, 2013, 108, 115-120.	6.4	30

#	Article	IF	CITATIONS
127	Hypoxia-inducible factor-1α(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. Blood Transfusion, 2013, 11, 553-7.	0.4	10
128	EBV-DNA In Peripheral Blood Of Patients With Diffuse Large B Cell Lymphoma: Associations With Patient Characteristics and Outcome. Blood, 2013, 122, 4243-4243.	1.4	0
129	Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia. Blood, 2013, 122, 860-860.	1.4	0
130	Primary Pancreatic Lymphoma in a Patient with Maturity Onset Diabetes of the Young type 3. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012005.	1.3	2
131	Epstein-Barr Virus (EBV)-associated Haemophagocytic Syndrome. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012008.	1.3	6
132	Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012040.	1.3	8
133	Prognostic Relevance of c- <i>Myc</i> and <i>BMI1</i> Expression in Patients With Glioblastoma. American Journal of Clinical Pathology, 2012, 138, 390-396.	0.7	34
134	von Hippel-Lindau Disease and Erythrocytosis. Journal of Clinical Oncology, 2012, 30, e137-e139.	1.6	16
135	Does "more―necessarily mean "better�. Blood, 2012, 119, 3194-3196.	1.4	Ο
136	Outcome of concurrent acute myeloid leukemia and granulocytic sarcoma: three clinical cases and a review of the literature. Comparative Clinical Pathology, 2012, 21, 725-730.	0.7	0
137	Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood, 2012, 119, 2219-2227.	1.4	78
138	Intralesional Interferon-α for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Ophthalmology, 2012, 119, 494-500.	5.2	44
139	A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death and Differentiation, 2012, 19, 1644-1654.	11.2	64
140	Interleukin-6 plasma levels are modulated by a polymorphism in the <i>NF-κB1</i> gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leukemia and Lymphoma, 2012, 53, 411-416.	1.3	36
141	Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. International Journal of Cancer, 2012, 130, 3006-3010.	5.1	28
142	The transient receptor potential vanilloidâ€⊋ cation channel impairs glioblastoma stemâ€like cell proliferation and promotes differentiation. International Journal of Cancer, 2012, 131, E1067-77.	5.1	71
143	Different impact of <i><scp>NOTCH</scp>1</i> and <i><scp>SF</scp>3B1</i> mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. British Journal of Haematology, 2012, 158, 426-429.	2.5	90
144	Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. Inflammatory Bowel Diseases, 2012, 18, 439-448.	1.9	25

#	Article	IF	CITATIONS
145	KRAS aKtive, an Italian network for assessment of KRAS mutations in colorectal cancer patients: Results on 7,432 cases Journal of Clinical Oncology, 2012, 30, e14042-e14042.	1.6	0
146	Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program Journal of Clinical Oncology, 2012, 30, e18021-e18021.	1.6	1
147	Predictive Biomarkers in NSCLC Patients Treated with Erlotinib after Chemotherapy: EGFR Expression or Mutations?. Annals of Oncology, 2012, 23, ix433.	1.2	0
148	The Contact with MDS Endothelial Cells Alters the Pattern of Lineage-Specific Gene Expression During Normal Hematopoietic Differentiation. Blood, 2012, 120, 1718-1718.	1.4	0
149	The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, 2011, 117, 3391-3401.	1.4	316
150	Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood, 2011, 117, 2700-2707.	1.4	111
151	Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation. Journal of Experimental Medicine, 2011, 208, 1389-1401.	8.5	565
152	Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. Neoplasia, 2011, 13, 1113-IN6.	5.3	115
153	Cervical extramedullary lymphomatoid granulomatosis. Journal of Clinical Neuroscience, 2011, 18, 851-853.	1.5	3
154	Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer, 2011, 10, 325-332.	2.3	78
155	Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood, 2011, 118, 5371-5379.	1.4	66
156	Gastrointestinal: An unusual gastric flat lesion: amyloidosis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 784-784.	2.8	0
157	Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: A pilot study. Cancer Science, 2011, 102, 1565-1567.	3.9	22
158	Mutations of <i>CD79A</i> , <i>CD79B</i> and <i>EZH2</i> genes in immunodeficiencyâ€related nonâ€Hodgkin lymphomas. British Journal of Haematology, 2011, 152, 777-780.	2.5	16
159	Advances in understanding the pathogenesis of familial thrombocythaemia. British Journal of Haematology, 2011, 152, 701-712.	2.5	37
160	Primary plasma cell leukemia followed by testicular plasmacytoma. International Journal of Hematology, 2011, 93, 224-227.	1.6	7
161	Epigenetic silencing of <i>SOCS3</i> identifies a subset of prostate cancer with an aggressive behavior. Prostate, 2011, 71, 318-325.	2.3	71
162	Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer, 2011, 117, 162-174.	4.1	80

#	Article	IF	CITATIONS
163	The Viral Load of Epstein–Barr Virus (EBV) DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma. Clinical Cancer Research, 2011, 17, 2885-2892.	7.0	89
164	Reply to S. Zucker. Journal of Clinical Oncology, 2011, 29, e43-e43.	1.6	0
165	Cauda equina enhancing lesion in a HIV-positive patient. Case report and literature revision Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011042.	1.3	2
166	Endoscopic Ultrasound-Guided Fine-Needle Aspiration With Liquid-Based Cytologic Preparation in the Diagnosis of Primary Pancreatic Lymphoma. Pancreas, 2010, 39, 1299-1302.	1.1	31
167	Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. Aids, 2010, 24, 2443-2450.	2.2	33
168	Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica, 2010, 95, 65-70.	3.5	79
169	Essential thrombocythemia as underlying cause of malabsorption syndrome. Annals of Hematology, 2010, 89, 1067-1068.	1.8	0
170	Genome wide DNAâ€profiling of HIVâ€related Bâ€cell lymphomas. British Journal of Haematology, 2010, 148, 245-255.	2.5	70
171	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 2010, 468, 824-828.	27.8	1,235
172	Thrombopoietin Receptor Activation, Thrombopoietin Mimetic Drugs, and Hereditary Thrombocytosis: Remarks on Bone Marrow Fibrosis. Journal of Clinical Oncology, 2010, 28, e317-e318.	1.6	9
173	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. Bone Marrow Transplantation, 2010, 45, 1668-1670.	2.4	14
174	Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin. Journal of Clinical Oncology, 2010, 28, 2538-2543.	1.6	86
175	Transferrin Receptor 2 Is Frequently and Highly Expressed in Glioblastomas. Translational Oncology, 2010, 3, 123-134.	3.7	106
176	Erratum to "Atypical sinonasal Schwannomas: A difficult diagnostic challenge―[Auris Nasus Larynx 36 (4) (2009) 482–486]. Auris Nasus Larynx, 2010, 37, 407.	1.2	0
177	Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. Aids, 2010, 24, 2408-2412.	2.2	27
178	Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. Blood, 2010, 116, 2425-2425.	1.4	1
179	The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. Blood, 2010, 116, 3601-3601.	1.4	Ο
180	Quantitation of EBV-DNA In Peripheral Blood In Hodgkin Lymphoma: Associations with Other Biomarkers and Patient Characteristics. Blood, 2010, 116, 2678-2678.	1.4	0

#	Article	IF	CITATIONS
181	Tumorigenic Potential of Olfactory Bulb-Derived Human Adult Neural Stem Cells Associates with Activation of TERT and NOTCH1. PLoS ONE, 2009, 4, e4434.	2.5	41
182	Comment re: Temozolomide Preferentially Depletes Cancer Stem Cells. Cancer Research, 2009, 69, 6364-6364.	0.9	1
183	Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Annals of Oncology, 2009, 20, 1408-1413.	1.2	110
184	Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Clinical Cancer Research, 2009, 15, 4415-4422.	7.0	189
185	Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. Journal of Neuro-Oncology, 2009, 94, 235-242.	2.9	66
186	The mutant <i>JAK2</i> <sup>V617F</sup> allele burden in children with essential thrombocythemia. British Journal of Haematology, 2009, 145, 430-432.	2.5	10
187	Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leukemia Research, 2009, 33, 1352-1356.	0.8	31
188	Atypical sinonasal Schwannomas: A difficult diagnostic challenge. Auris Nasus Larynx, 2009, 36, 482-486.	1.2	20
189	Intravascular large B cell lymphoma: when lymphoma is suspected but routine diagnostic work-up is negative. Leukemia and Lymphoma, 2009, 50, 1900-1903.	1.3	4
190	Patchy Left-Sided Colitis: Primary Eosinophilic Colitis or Paraneoplastic Syndrome?. Clinical Gastroenterology and Hepatology, 2009, 7, e61.	4.4	1
191	Waterâ€immersion Technique During Standard Upper Endoscopy May Be Useful to Drive the Biopsy Sampling of Duodenal Mucosa in Children With Celiac Disease. Journal of Pediatric Gastroenterology and Nutrition, 2009, 49, 411-416.	1.8	26
192	Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica, 2009, 94, 1368-1374.	3.5	53
193	The Water Immersion Technique is Easy to Learn for Routine Use During EGD for Duodenal Villous Evaluation. Journal of Clinical Gastroenterology, 2009, 43, 244-248.	2.2	33
194	COMBINED MODALITY TREATMENT INCLUDING METHOTREXATE-BASED CHEMOTHERAPY FOR PRIMARY CEREBRAL NERVOUS SYSTEM LYMPHOMA: A SINGLE INSTITUTION EXPERIENCE. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009020.	1.3	2
195	INTRODUCING MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009001.	1.3	0
196	Clinical and Biological Features, Treatment and Long-Term Outcome of 65 Children with Ph- Myeloprolipherative Disorders (MPD) Blood, 2009, 114, 1889-1889.	1.4	0
197	Paediatric Kikuchi–Fujimoto disease: A benign cause of fever and lymphadenopathy. Pediatric Blood and Cancer, 2008, 50, 119-123.	1.5	13
198	Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. International Journal of Cancer, 2008, 122, 1236-1242.	5.1	32

#	Article	IF	CITATIONS
199	Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. International Journal of Cancer, 2008, 123, 1586-1592.	5.1	50
200	Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. International Journal of Cancer, 2008, 123, 2955-2960.	5.1	74
201	Role of the life span determinant P66shcA in ethanol-induced liver damage. Laboratory Investigation, 2008, 88, 750-760.	3.7	69
202	Mesenchymal differentiation of glioblastoma stem cells. Cell Death and Differentiation, 2008, 15, 1491-1498.	11.2	97
203	Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. World Journal of Surgical Oncology, 2008, 6, 111.	1.9	14
204	Optimal band imaging system: a new tool for enhancing the duodenal villous pattern in celiac disease. Gastrointestinal Endoscopy, 2008, 68, 352-357.	1.0	30
205	Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme. Clinical Cancer Research, 2008, 14, 8205-8212.	7.0	327
206	Phosphorylated STAT5 Represents a New Possible Prognostic Marker in Hodgkin Lymphoma. American Journal of Clinical Pathology, 2008, 129, 472-477.	0.7	18
207	Chronic Lymphocytic Leukemia With Eyelid Involvement Responding to Alemtuzumab. Journal of Clinical Oncology, 2008, 26, 5299-5301.	1.6	1
208	Reply to Souza et al Endoscopy, 2008, 40, 621-621.	1.8	0
209	Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. Haematologica, 2008, 93, 169-172.	3.5	29
210	Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. Haematologica, 2008, 93, 1178-1185.	3.5	26
211	Congenital Tumors of the Retrorectal Space in the Adult: Report of Two Cases and Review of the Literature. Tumori, 2008, 94, 602-607.	1.1	15
212	A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica, 2008, 93, 1068-1071.	3.5	64
213	Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. Blood, 2008, 112, 778-778.	1.4	0
214	Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia. Journal of Clinical Oncology, 2007, 25, 1048-1053.	1.6	107
215	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2007, 48, 564-569.	1.3	14
216	A highly accurate method for monitoring histological recovery in patients with celiac disease on a gluten-free diet using an endoscopic approach that avoids the need for biopsy: a double-center study. Endoscopy, 2007, 39, 46-51.	1.8	41

#	Article	IF	CITATIONS
217	Hydrogen peroxide-related colitis (previously known as â€pseudolipomatosis"): a series of cases occurring in an epidemic pattern. Endoscopy, 2007, 39, 916-919.	1.8	16
218	Extremely delayed falx metastasis from renal cell carcinoma. Neurology, 2007, 68, 1541-1542.	1.1	4
219	Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood, 2007, 110, 354-359.	1.4	71
220	Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 1026-1030.	1.6	11
221	Role of the "Immersion Technique―in Diagnosing Celiac Disease With Villous Atrophy Limited to the Duodenal Bulb. Journal of Clinical Gastroenterology, 2007, 41, 571-575.	2.2	27
222	Posttransplant Lymphoproliferative Disorders After Liver Transplantation: Analysis of Early and Late Cases in a 255 Patient Series. Transplantation Proceedings, 2007, 39, 1956-1960.	0.6	25
223	Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Annals of Oncology, 2007, 18, 1376-1381.	1.2	47
224	The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood, 2007, 110, 3384-3386.	1.4	50
225	Accuracy and Learning Curve and of the Water-Immersion Technique in Assessing Marked Villous Atrophy of the Duodenum: A Single Centre 4-Year Experience. Gastrointestinal Endoscopy, 2007, 65, AB339.	1.0	1
226	Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. Journal of Infection, 2007, 54, 298-306.	3.3	20
227	Genome Wide-DNA Profiling of HIV-Related Non-Hodgkin Lymphomas: Implications for Disease Pathogenesis and Histogenesis Blood, 2007, 110, 561-561.	1.4	9
228	Overexpression of <1>PRV-1 1 Gene in Polycythemia Rubra Vera and Essential Thrombocythemia. , 2006, 125, 265-274.		5
229	Ischaemic jejunal vasculitis during treatment with pegylated interferon-alpha 2b and ribavirin for hepatitis C virus related cirrhosis. Digestive and Liver Disease, 2006, 38, 352-354.	0.9	8
230	Duodenal metastasis from a primary angiosarcoma of the colon. Gastrointestinal Endoscopy, 2006, 63, 330.	1.0	10
231	High accuracy and costâ€effectiveness of a biopsyâ€avoiding endoscopic approach in diagnosing coeliac disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 61-69.	3.7	38
232	Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. British Journal of Cancer, 2006, 95, 1108-1113.	6.4	69
233	Chemotherapy resistance of glioblastoma stem cells. Cell Death and Differentiation, 2006, 13, 1238-1241.	11.2	578
234	Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts. International Journal of Cancer, 2006, 118, 2158-2167.	5.1	39

#	Article	IF	CITATIONS
23	<sup>5</sup> Influence of local environment on the differentiation of neural stem cells engrafted onto the injured spinal cord. Neurological Research, 2006, 28, 488-492.	1.3	39
23	<ul> <li>Telomerase inhibition impairs tumor growth in glioblastoma xenografts. Neurological Research,</li> <li>2006, 28, 532-537.</li> </ul>	1.3	19
23	Delayed Allergy to Aminopenicillins: Clinical and Immunological Findings. International Journal of Immunopathology and Pharmacology, 2006, 19, 831-840.	2.1	16
23	Establishing tumor cell lines from aggressive telomerase-positive chordomas of the skull base. Journal of Neurosurgery, 2006, 105, 482-484.	1.6	17
23	9 NK/T-cell lymphomas â€~nasal type': an Italian multicentric retrospective survey. Annals of Oncology, 2006, 17, 794-800.	1.2	69
24	O DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. Haematologica, 2006, 91, 1252-6.	3.5	10
24	<ul> <li>Intrathymic deficient expansion of T cell precursors in Down syndrome. American Journal of Medical</li> <li>Genetics Part A, 2005, 37, 219-224.</li> </ul>	2.4	6
24	<ul> <li>Morphological and immunohistochemical study of Down syndrome thymus. American Journal of</li> <li>Medical Genetics Part A, 2005, 37, 225-230.</li> </ul>	2.4	33
24	Are gadolinium contrast agents suitable for gadolinium neutron capture therapy?. Neurological Research, 2005, 27, 387-398.	1.3	58
24	<ul> <li>Inhibition of DNA Methylation Sensitizes Glioblastoma for Tumor Necrosis Factor–Related</li> <li>Apoptosis-Inducing Ligand–Mediated Destruction. Cancer Research, 2005, 65, 11469-11477.</li> </ul>	0.9	81
24	<sup>5</sup> Characterization of Cell Death Pathways in Human Immunodeficiency Virus-Associated Encephalitis. American Journal of Pathology, 2005, 167, 695-704.	3.8	33
24	6 Polymorphism in Cytokine Genes as Prognostic Marker in Hodgkin's Lymphoma Blood, 2005, 106, 21-21.	1.4	2
24	<ul> <li>Combined Muliparameter Approach to the Diagnosis of Polycythemia Vera and Essential</li> <li>Thrombocythemia Blood, 2005, 106, 4950-4950.</li> </ul>	1.4	0
24	<ul> <li>Molecular Analysis of Immunoglobulin Variable Genes in HIV-Related Non-Hodgkin Lymphoma:</li> <li>Implications for Disease Pathogenesis and Histogenesis Blood, 2005, 106, 330-330.</li> </ul>	1.4	0
24	Role of <i>p16/INK4a</i> in Gastrointestinal Stromal Tumor Progression. American Journal of Clinical Pathology, 2004, 122, 35-43.	0.7	52
25	o Role of p16/INK4a in Gastrointestinal Stromal Tumor Progression. American Journal of Clinical Pathology, 2004, 122, 35-43.	0.7	25
25	Role of <i>PTEN</i> in Gastrointestinal Stromal Tumor Progression. Archives of Pathology and Laboratory Medicine, 2004, 128, 421-425.	2.5	22
25	2 T/NK "Nasal Type―Lymphomas: An Italian Cooperative Retrospective Survey Blood, 2004, 104, 4578-4578.	1.4	0

#	Article	IF	CITATIONS
253	Mutations of theBIK gene in human peripheral B-cell lymphomas. Genes Chromosomes and Cancer, 2003, 38, 91-96.	2.8	51
254	Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis. Leukemia, 2003, 17, 919-924.	7.2	55
255	Chordoma of the skull base: predictors of tumor recurrence. Journal of Neurosurgery, 2003, 98, 812-822.	1.6	95
256	Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood, 2003, 102, 1833-1841.	1.4	137
257	Glioblastoma induces vascular endothelial cells to express telomerase in vitro. Cancer Research, 2003, 63, 3750-4.	0.9	29
258	Overexpression of the Polycythemia Rubra Vera-1 Gene in Essential Thrombocythemia. Journal of Clinical Oncology, 2002, 20, 4249-4254.	1.6	51
259	The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood, 2002, 100, 714-717.	1.4	40
260	Expression of Cyclin-Dependent Kinase Inhibitor p27Kip1 in AIDS-Related Diffuse Large-Cell Lymphomas Is Associated with Epstein-Barr Virus-Encoded Latent Membrane Protein 1. American Journal of Pathology, 2002, 161, 163-171.	3.8	11
261	Relationship Between Gastric Localization of Hepatitis C Virus and Mucosa-associated Lymphoid Tissue in Helicobacter pylori Infection. Scandinavian Journal of Gastroenterology, 2002, 37, 1126-1132.	1.5	6
262	Characterization of Epstein–Barr Virus Genotype in AIDS-Related Non-Hodgkin's Lymphoma. AIDS Research and Human Retroviruses, 2002, 18, 19-26.	1.1	16
263	Possible involvement ofhMLH1, p16INK4a andPTEN in the malignant transformation of endometriosis. International Journal of Cancer, 2002, 102, 398-406.	5.1	128
264	Telomerase in brain tumors. Child's Nervous System, 2002, 18, 112-117.	1.1	38
265	Molecular histogenesis of plasmablastic lymphoma of the oral cavity. British Journal of Haematology, 2002, 119, 622-628.	2.5	77
266	Simultaneous presentation of Waldenstrom's macroglobulinemia and acute myeloid leukemia. Haematologica, 2002, 87, EIM07.	3.5	0
267	Absence of structural mutations of the BAK gene in B cell lymphomas. Haematologica, 2002, 87, 661-2.	3.5	3
268	Dysregulated expression of Bcl-xL in CD34+ cells isolated from patients with refractory anemia with excess of blasts during megakaryocytic differentiation. Haematologica, 2002, 87, 1342-3.	3.5	4
269	Relationship between gastric localization of hepatitis C virus and gastric mucosa-associated lymphoid tissue related to Helicobacter pylori infection. Gastroenterology, 2001, 120, A746-A747.	1.3	0
270	Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood, 2001, 97, 1063-1069.	1.4	74

#	Article	IF	CITATIONS
271	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. Aids, 2001, 15, 1483-1491.	2.2	175
272	Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus–related lymphomas. Blood, 2001, 97, 744-751.	1.4	224
273	Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98, 495-497.	1.4	42
274	Quercetin and tamoxifen sensitize human melanoma cells to hyperthermia. Melanoma Research, 2001, 11, 469-476.	1.2	36
275	Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 159-165.	2.8	24
276	Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells. Journal of Neurosurgery, 2001, 94, 961-971.	1.6	36
277	Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. International Journal of Cancer, 2000, 85, 438-445.	5.1	137
278	Mutation ofBAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. , 2000, 27, 177-182.		9
279	In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. International Journal of Cancer, 2000, 88, 895-901.	5.1	40
280	Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Experimental Hematology, 2000, 28, 519-526.	0.4	37
281	Phenotypic change of human cultured meningioma cells. Journal of Neuro-Oncology, 2000, 49, 9-17.	2.9	15
282	Epstein-Barr Virus Infection Is Predictive of CNS Involvement in Systemic AIDS-Related Non-Hodgkin's Lymphomas. Journal of Clinical Oncology, 2000, 18, 3325-3330.	1.6	92
283	Brief Report: Disseminated Mycobacteriosis Caused by Drug-Resistant Mycobacterium triplex in a Human Immunodeficiency Virus-Infected Patient during Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2000, 31, 177-179.	5.8	25
284	Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. Haematologica, 2000, 85, 1019-23.	3.5	4
285	Non-AIDS-defining neoplasms and HIV infection International Journal of Molecular Medicine, 1999, 4, 639-43.	4.0	1
286	Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. Annals of Neurology, 1999, 45, 259-261.	5.3	37
287	Clinical usefulness of patch and challenge tests in the diagnosis of cell-mediated allergy to betalactams. Annals of Allergy, Asthma and Immunology, 1999, 83, 257-266.	1.0	59
288	Value of Combined Approach With Thallium-201 Single-Photon Emission Computed Tomography and Epstein-Barr Virus DNA Polymerase Chain Reaction in CSF for the Diagnosis of AIDS-Related Primary CNS Lymphoma. Journal of Clinical Oncology, 1999, 17, 554-554.	1.6	167

#	Article	IF	CITATIONS
289	HHVâ€8/KSHV is Not Associated with AIDSâ€Related Primary Central Nervous System Lymphoma. Brain Pathology, 1999, 9, 199-208.	4.1	26
290	Epsteinâ€Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome–related primary central nervous system lymphoma. Annals of Neurology, 1999, 45, 259-261.	5.3	1
291	Minimally Invasive Diagnosis of Acquired Immunodeficiency Syndrome-Related Primary Central Nervous System Lymphoma. Journal of the National Cancer Institute, 1998, 90, 364-369.	6.3	117
292	Neurofibromatosis type 2: growth stimulation of mixed acoustic schwannoma by concurrent adjacent meningioma: possible role of growth factors. Journal of Neurosurgery, 1998, 89, 149-154.	1.6	25
293	Neurofibromatosis type 2: growth stimulation of mixed acoustic schwannoma by concurrent adjacent meningioma: possible role of growth factors. Neurosurgical Focus, 1998, 4, E11.	2.3	1
294	Expression of p53, Bcl-2, and Bax in CD34+ Cells Recovering After Chemotherapy. Blood, 1998, 92, 4880-4881.	1.4	7
295	Expression of p53, Bcl-2, and Bax in CD34+ Cells Recovering After Chemotherapy. Blood, 1998, 92, 4880-4881.	1.4	Ο
296	Analysis of Human Herpesvirus Type 8 Infection in AIDS-Related and AIDS-Unrelated Primary Central Nervous System Lymphoma. Journal of Infectious Diseases, 1997, 175, 1193-1197.	4.0	31
297	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. European Journal of Gastroenterology and Hepatology, 1997, 9, 307-310.	1.6	26
298	Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat-shock protein-70. , 1997, 73, 75-83.		32
299	Quercetin and the Growth of Leukemic Progenitors. Leukemia and Lymphoma, 1996, 23, 49-53.	1.3	20
300	Severe anaemia as first sign of metastatic alveolar rhabdomyosarcoma. European Journal of Haematology, 1996, 57, 109-110.	2.2	1
301	Evaluation of cerebrospinal fluid EBVâ€DNA and ILâ€10 as markers for <i>in vivo</i> diagnosis of AIDSâ€related primary central nervous system lymphoma. British Journal of Haematology, 1995, 90, 844-849.	2.5	121
302	Tamoxifen and Quercetin Interact with Type II Estrogen Binding Sites and Inhibit the Growth of Human Melanoma Cells. Journal of Investigative Dermatology, 1995, 105, 248-253.	0.7	75
303	Detection of growth hormone-producing cells in human thymus by immunohistochemistry and non-radioactive in situ hybridization Journal of Histochemistry and Cytochemistry, 1994, 42, 1349-1354.	2.5	50
304	Growth-Inhibitory Effect of Quercetin and Presence of Type II Estrogen Binding Sites in Primary Human Transitional Cell Carcinomas. Journal of Urology, 1994, 152, 1029-1033.	0.4	25
305	Type II estrogen binding sites and antiproliferative activity of quercetin in human meningiomas. Cancer, 1993, 71, 193-198.	4.1	34
306	A Leukemic Patient with Hepatosplenic Abscesses Due to Coagulase-Negative Staphylococci. Clinical Infectious Diseases, 1992, 14, 364-365.	5.8	8

#	Article	IF	CITATIONS
307	The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth. Leukemia Research, 1992, 16, 497-503.	0.8	49
308	Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. International Journal of Cancer, 1992, 50, 486-492.	5.1	162
309	Acute onset of juvenile myelodysplastic syndrome mimicking thrombotic thrombocytopenic purpura and rapidly evolving in overt myeloid leukemia. American Journal of Hematology, 1992, 41, 64-65.	4.1	7
310	Premenopausal cytomegalovirus oophoritis in a patient with AIDS. Aids, 1991, 5, 458.	2.2	13
311	Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. British Journal of Haematology, 1991, 79, 562-566.	2.5	51
312	Detection of mRNA and hnRNA using a digoxigenin labelled cDNA probe byin situ hybridization on frozen tissue sections. The Histochemical Journal, 1991, 23, 69-74.	0.6	11
313	Interleukin-2 Receptor Expression in Human Mast Cells and Basophils. International Archives of Allergy and Immunology, 1990, 91, 8-14.	2.1	22
314	Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. British Journal of Cancer, 1990, 62, 942-946.	6.4	125
315	Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids. British Journal of Haematology, 1990, 75, 489-495.	2.5	83
316	Immunocytochemical distribution of S-100 protein in patients with Down's syndrome. Acta Neuropathologica, 1990, 80, 475-478.	7.7	9
317	Type-II estrogen binding sites in a lymphoblastoid cell line and growth-inhibitory effect of estrogen, anti-estrogen and bioflavonoids. International Journal of Cancer, 1990, 46, 1112-1116.	5.1	65
318	Neuropeptide-immunoreactive cells in human thymus. Brain, Behavior, and Immunity, 1990, 4, 189-197.	4.1	20
319	Membrane Structures Involved in the Proliferation and Differentiation of T-cell Precursors. Annals of the New York Academy of Sciences, 1988, 551, 378-379.	3.8	0
320	Alterations in thymocyte subpopulations in Down's syndrome (trisomy 21). Clinical Immunology and Immunopathology, 1988, 49, 175-186.	2.0	33
321	T-cell antigen receptor expression in the thymus. Human Immunology, 1987, 18, 93-110.	2.4	8
322	Phenotypical characteristics and proliferative capabilities of thymocyte subsets in human thymoma. Clinical Immunology and Immunopathology, 1986, 40, 385-392.	2.0	2
323	OKT4/OKT8 ratio and serum beta 2-microglobulin in mycosis fungoides and chronic benign dermatitis. European Journal of Cancer & Clinical Oncology, 1986, 22, 663-669.	0.7	2
324	T Lymphocyte Subsets and Platelet-Associated IgG in Idiopathic Thrombocytopenic Purpura: Effect of Splenectomy. Acta Haematologica, 1986, 75, 83-88.	1.4	2

#	Article	IF	CITATIONS
325	Inhibitory effect of cyclosporin A on the OKT3-induced peripheral blood lymphocyte proliferation. Cellular Immunology, 1986, 97, 131-139.	3.0	20
326	Transient deficiency of peripheral blood accessory cells in supporting T cell mitogenesis in patients suffering from chronic idiopathic thrombocytopenic purpura after intravenous gammaglobulin treatment. Blut, 1985, 51, 1-10.	1.2	14
327	T-lymphocyte subpopulations in systemic lupus erythematosus in pregnancy. American Journal of Obstetrics and Gynecology, 1984, 149, 103-104.	1.3	0